Literature DB >> 16781800

Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge.

Julia Vipond1, Richard Vipond, Emma Allen-Vercoe, Simon O Clark, Graham J Hatch, Karen E Gooch, Joanna Bacon, Toby Hampshire, Helen Shuttleworth, Nigel P Minton, Karen Blake, Ann Williams, Philip D Marsh.   

Abstract

Putative TB vaccine candidates were selected from lists of genes induced in response to in vivo-like stimuli, such as low oxygen and carbon starvation or growth in macrophages, and tested as plasmid DNA vaccines for their ability to protect against Mycobacterium tuberculosis challenge in a guinea pig aerosol infection model. This vaccination method was chosen as it induces the Th1 cell-mediated immune response required against intracellular pathogens such as M. tuberculosis. Protection was assessed in the guinea pig model in terms of mycobacteria present in the lungs at 30 days post-challenge. Protection achieved by the novel candidates was compared to BCG (positive control) and saline (negative control). Four vaccines encoding for proteins such as PE and PPE proteins, a zinc metalloprotease and an acyltransferase, gave a level of protection that was statistically better than saline in the lungs. These findings have enabled us to focus on a sub-set of vaccine candidates for further evaluation using additional vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16781800     DOI: 10.1016/j.vaccine.2006.05.025

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice.

Authors:  Jiu ling Wang; Ya qing Qie; Bing dong Zhu; Hong mei Zhang; Ying Xu; Qing zhong Wang; Jia zhen Chen; Wei Liu; Hong hai Wang
Journal:  Med Microbiol Immunol       Date:  2008-05-20       Impact factor: 3.402

2.  Putative roles of a proline-glutamic acid-rich protein (PE3) in intracellular survival and as a candidate for subunit vaccine against Mycobacterium tuberculosis.

Authors:  Susmita K Singh; Ruma Kumari; Diwakar K Singh; Sameer Tiwari; Pramod K Singh; Sharad Sharma; Kishore K Srivastava
Journal:  Med Microbiol Immunol       Date:  2013-05-25       Impact factor: 3.402

3.  Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis.

Authors:  Sylvie Bertholet; Gregory C Ireton; Maria Kahn; Jeffrey Guderian; Raodoh Mohamath; Nicole Stride; Elsa M Laughlin; Susan L Baldwin; Thomas S Vedvick; Rhea N Coler; Steven G Reed
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

4.  Comparative analysis of Mycobacterium tuberculosis pe and ppe genes reveals high sequence variation and an apparent absence of selective constraints.

Authors:  Christopher R E McEvoy; Ruben Cloete; Borna Müller; Anita C Schürch; Paul D van Helden; Sebastien Gagneux; Robin M Warren; Nicolaas C Gey van Pittius
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

Review 5.  Mycobacterial PE/PPE proteins at the host-pathogen interface.

Authors:  Samantha L Sampson
Journal:  Clin Dev Immunol       Date:  2011-01-26

6.  Enhanced serodiagnostic potential of a fusion molecule consisting of Rv1793, Rv2628 and a truncated Rv2608 of Mycobacterium tuberculosis.

Authors:  Sadaf Sulman; Saher Shahid; Aasia Khaliq; Atiqa Ambreen; Imran H Khan; Andrea M Cooper; Muhammad Waheed Akhtar
Journal:  PLoS One       Date:  2021-11-12       Impact factor: 3.240

7.  Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses.

Authors:  Anat Zvi; Naomi Ariel; John Fulkerson; Jerald C Sadoff; Avigdor Shafferman
Journal:  BMC Med Genomics       Date:  2008-05-28       Impact factor: 3.063

8.  A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model.

Authors:  Karen R Buttigieg; Stuart D Dowall; Stephen Findlay-Wilson; Aleksandra Miloszewska; Emma Rayner; Roger Hewson; Miles W Carroll
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

9.  A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease.

Authors:  S D Dowall; K R Buttigieg; S J D Findlay-Wilson; E Rayner; G Pearson; A Miloszewska; V A Graham; M W Carroll; R Hewson
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.